FDA Accepts BLA for Subcutaneous Autoinjector Formulation of Lecanemab

In the pivotal phase 3 Clarity AD trial, treatment with a subcutaneous autoinjector of lecanemab led to reduced rates of amyloid-related imaging abnormalities while maintaining similar bioequivalence levels to the original formulation.:

Source: Neurology Read More